The trial anchors are STEP for semaglutide ( NEJM , 2021), SURMOUNT for tirzepatide ( NEJM , 2022), and SURMOUNT-OSA for tirzepatide in sleep apnea ( NEJM , 2024)
Standard BMI categories are: Underweight: BMI less than 18.5 kg/m2 Healthy weight: BMI of 18.5 to less than 25 kg/m2 Overweight: BMI of 25 to less than 30 kg/m2 Obesity: BMI of 30 kg/m2 or more Class 1 obesity: 30 to less than 35 kg/m2 Class 2 obesity: 35 to less than 40 kg/m2 Class 3 obesity: 40 kg/m2 or more FDA-approved weight loss drugs are typically prescribed for adults with obesity (BMI of 30 or more) or overweight (BMI of 27 or more) plus a weight-related medical condition
Funding The authors declare that no financial support was received for the research and/or publication of this article
Semaglutide GLP-1 , Cagrilintide
Takasu M, Kishi S, Nagasu H, Kidokoro K, Brooks CR, Kashihara N
These medications operate through completely distinct mechanisms: Wegovy acts systemically on GLP-1 receptors affecting metabolic pathways, whilst botulinum toxin works locally at the neuromuscular junction to inhibit acetylcholine release
